From: A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females
Input parameters | Base Case Value | References |
---|---|---|
Vaccination | Â | Â |
Efficacy HPV 16/18 | 98% (95% CI: 88.4-1000) | |
Efficacy non-vaccine oncogenic HPV types | 37% (95% CI: 7.4-58.0) | |
Duration of vaccine protection | lifelong | Assumption |
Coverage rate | 75% | Assumption based on [50] |
Screening | Â | Â |
Age and frequency | Age 18-69, 70% (once/3 years), 12% (never) | [39] |
Cytology (Pap) test sensitivity | 55.4% | [57] |
Cytology (Pap) test specificity | 96.8% | [57] |
Costs and utilities | Â | Â |
Vaccination costs | Â | Â |
Vaccine per dose | $135.00 | Assumption |
Screening Costs | Â | Â |
Conventional cytology | $57 | |
Colposcopy + Biopsy | $150 | |
Treatment Costs (annual) | Â | Â |
CIN 1 | $782 | |
CIN 2/3 | $1,353 | |
Cervical cancer stage 1 | $11,915 | |
Cervical cancer stage 2 | $18,851 | |
Cervical cancer stage 3 | $18,851 | |
Cervical cancer stage 4 | $25,759 | |
Utilities | Â | Â |
Normal Population | 0.94-0.89 (age-specific) | [58] |
CIN lesion | 0.96-0.995 | |
Cervical cancer | 0.73 | |
Cured cancer | 0.94 | [61] |